Publication date: 2 October 2026 Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 150 Author(s): Ellen E. Towers, Hugh P. Garavan, Gezelle Dali, Cassandra Wannan, Warren Logge, Paul Haber, Devarshi Pancholi, Anthony Juliano, Ahmed Hussain, Courtney C. Haswell, Delin Sun, C. Lexi Baird, Miranda Olff, Jessie L. Frijling, Dick J. Veltman, Saskia B.J. Koch, Laura Nawjin, Mirjam van Zuiden, Emily L. Dennis, David F. Tate
Brain structural covariance networks in co-occurring PTSD and alcohol use disorder: An ENIGMA PTSD and ENIGMA addiction working group collaboration. // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – URL: https://www.sciencedirect.com/science/article/pii/S0278584626003568?dgcid=rss_sd_all
Brain structural covariance networks in co-occurring PTSD and alcohol use disorder: An ENIGMA PTSD and ENIGMA addiction working group collaboration. Progress in Neuro-Psychopharmacology & Biological Psychiatry. https://www.sciencedirect.com/science/article/pii/S0278584626003568?dgcid=rss_sd_all
“Brain structural covariance networks in co-occurring PTSD and alcohol use disorder: An ENIGMA PTSD and ENIGMA addiction working group collaboration.” Progress in Neuro-Psychopharmacology & Biological Psychiatry.
@article{article90528,
title = {Brain structural covariance networks in co-occurring PTSD and alcohol use disorder: An ENIGMA PTSD and ENIGMA addiction working group collaboration},
journal = {Progress in Neuro-Psychopharmacology \& Biological Psychiatry},
url = {https://www.sciencedirect.com/science/article/pii/S0278584626003568?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...